ReviewDrugs2021
The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- The Prevalence and Risk Factors of Residual Back Pain After Vertebroplasty for Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis.Orthopaedic surgery · 2025Pooled it
- Bone Marrow Immunometabolic Remodeling in Osteoporosis: From Systemic Risk Factors to Precision Intervention.International journal of general medicine · 2026Review
- An injectable phosphocreatine-grafted hydrogel incorporating hierarchically structured teriparatide/SrZnP-functionalized Zn-Cu particles for osteogenesis-angiogenesis coupling and osteoporotic bone regeneration.Materials today. Bio · 2025Article
- Mild photothermal-mediated neuroimmunomodulatory composite hydrogel ameliorates bone healing microenvironment for enhanced osteoporotic bone defect regeneration.Materials today. Bio · 2025Article
- The hidden driver of osteoporosis: mitochondria-dominated inflammation.Cell communication and signaling : CCS · 2025Review
- Progress of research on the gut microbiome and its metabolite short-chain fatty acids in postmenopausal osteoporosis: a literature review.Frontiers of medicine · 2025Review
- Biomaterial-based strategies for bone cement: modulating the bone microenvironment and promoting regeneration.Journal of nanobiotechnology · 2025Review
- Exon junction complexes regulate osteoclast-induced bone resorption by influencing the NFATc1 m6A distribution through the "shield effect".Clinical and translational medicine · 2025Article
- Mendelian randomization analysis: exploring the causal relationship between menstrual cycle length and bone mineral density.Archives of medical science : AMS · 2025Article
- The mediating role of caffeine and biological age in the association between dietary index for gut microbiota and osteoporosis.Frontiers in nutrition · 2025Article
- Incident Vertebral Fractures During Romosozumab Treatment in a Patient With a PathogenicJCEM case reports · 2025Article
- Melatonin-loaded bioactive microspheres accelerate aged bone regeneration by formation of tunneling nanotubes to enhance mitochondrial transfer.Materials today. Bio · 2024Article
- Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies.CNS drugs · 2024Article
- Olink and gut microbial metabolomics reveal new biomarkers for the prediction and diagnosis of PMOP.Journal of bone and mineral metabolism · 2024Review
- Potential association of rheumatic diseases with bone mineral density and fractures: a bi-directional mendelian randomization study.BMC musculoskeletal disorders · 2024Article
- Article
- Evaluation of nutrient composition and bone-promoting activity of miiuy croaker (Frontiers in nutrition · 2024Article
- Association of diuretics with falls and wrist fractures: a Mendelian randomization study.Frontiers in public health · 2024Article
- Identification and experimental validation of programmed cell death- and mitochondria-associated biomarkers in osteoporosis and immune microenvironment.Frontiers in genetics · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a highly prevalent bone disease affecting more than 37.5 million individuals in the European Union (EU) and the United States of America (USA). It is characterized by low bone mineral density (BMD), impaired bone quality, and loss of structural and biomechanical properties, resulting in reduced bone strength. An increase in morbidity and mortality is seen in patients with osteoporosis, caused by the approximately 3.5 million new osteoporotic fractures occurring every year in the EU. Currently, different medications are available for the treatment of osteoporosis, including anti-resorptive and osteoanabolic medications. Bisphosphonates, which belong to the anti-resorptive medications, are the standard treatment for osteoporosis based on their positive effects on bone, long-term experience, and low costs. However, not only medications used for the treatment of osteoporosis can affect bone: several other medications are suggested to have an effect on bone as well, especially on fracture risk and BMD. Knowledge about the positive and negative effects of different medications on both fracture risk and BMD is important, as it can contribute to an improvement in osteoporosis prevention and treatment in general, and, even more importantly, to the individual's health. In this review, we therefore discuss the effects of both osteoporotic and non-osteoporotic medications on fracture risk and BMD. In addition, we discuss the underlying mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.